An Activated Protein C Analog With Reduced Anticoagulant Activity Extends the Therapeutic Window of Tissue Plasminogen Activator for Ischemic Stroke in Rodents

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Stroke

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/STROKEAHA.112.658997PMID 22811462PMCID PMC3429704
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thrombolytic therapy for acute ischemic stroke beyond three hours.

  2011cited by this paper
• Cytoprotective protein C pathways and implications for stroke and neurological disorders.

  2011cited by this paper
• Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact.

  2010cited by this paper
• Thrombolysis With Plasmin: Implications for Stroke Treatment

  2010cited by this paper
• Alteplase for ischaemic stroke--much sooner is much better.

  2010cited by this paper
• Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic.

  2009cited by this paper
• The APCs of neuroprotection.

  2009cited by this paper
• Netrin-4 Enhances Angiogenesis and Neurologic Outcome after Cerebral Ischemia

  2009cited by this paper
• Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells.

  2009cited by this paper
• Species‐dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity

  2009cited by this paper
• Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity

  2009cited by this paper
• Endothelial Protein C Receptor-Assisted Transport of Activated Protein C across the Mouse Blood—Brain Barrier

  2009cited by this paper
• Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity.

  2009cited by this paper
• Activated Protein C Promotes Neovascularization and Neurogenesis in Postischemic Brain via Protease-Activated Receptor 1

  2008cited by this paper
• National US Estimates of Recombinant Tissue Plasminogen Activator Use: ICD-9 Codes Substantially Underestimate

  2008cited by this paper
• Effects of activated protein C on neonatal hypoxic ischemic brain injury.

  2008cited by this paper
• Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C

  2007cited by this paper
• Activated protein C inhibits tissue plasminogen activator–induced brain hemorrhage

  2006cited by this paper
• Functional recovery after embolic stroke in rodents by activated protein C

  2005cited by this paper
• Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation.

  2005cited by this paper
• Activated Protein C Mediates Novel Lung Endothelial Barrier Enhancement

  2005cited by this paper
• Analysis of Combined Treatment of Embolic Stroke in Rat with r-tPA and a GPIIb/IIIa Inhibitor

  2005cited by this paper
• Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3.

  2004cited by this paper
• Intracerebral Hemorrhage: Effects of Aging on Brain Edema and Neurological Deficits

  2004cited by this paper
• Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C

  2004cited by this paper
• Activated protein C variants with normal cytoprotective but reduced anticoagulant activity.

  2004cited by this paper
• VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena.

  2004cited by this paper
• Intravenous Administration of a GPIIb/IIIa Receptor Antagonist Extends the Therapeutic Window of Intra-Arterial Tenecteplase–Tissue Plasminogen Activator in a Rat Stroke Model

  2004cited by this paper
• Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective

  2003cited by this paper
• Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1.

  2003cited by this paper
• Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.

  2003cited by this paper
• Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor.

  2003cited by this paper
• Involvement of Matrix Metalloproteinase in Thrombolysis-Associated Hemorrhagic Transformation After Embolic Focal Ischemia in Rats

  2002cited by this paper
• Molecular Characterization of an Extended Binding Site for Coagulation Factor Va in the Positive Exosite of Activated Protein C*

  2002cited by this paper
• Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-&kgr;B

  2002cited by this paper
• Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway

  2002cited by this paper
• Therapeutic Benefit of Intravenous Administration of Bone Marrow Stromal Cells After Cerebral Ischemia in Rats

  2001cited by this paper
• Anti-Inflammatory, Antithrombotic, and Neuroprotective Effects of Activated Protein C in a Murine Model of Focal Ischemic Stroke

  2001cited by this paper
• Magnetic Resonance Imaging Indexes of Therapeutic Efficacy of Recombinant Tissue Plasminogen Activator Treatment of Rat at 1 and 4 Hours after Embolic Stroke

  2000cited by this paper
• Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance.

  1999cited by this paper
• Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.

  1999cited by this paper
• VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain.

  1999cited by this paper
• Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia

  1999cited by this paper
• Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice

  1998cited by this paper
• Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.

  1997cited by this paper
• A rat model of focal embolic cerebral ischemia.

  1997cited by this paper
• Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice.

  1997cited by this paper
• Reduction of Infarct Volume and Mortality by Thrombolysis in a Rat Embolic Stroke Model

  1992cited by this paper
• A Semiautomated Method for Measuring Brain Infarct Volume

  1990cited by this paper
• “Model”

  1981cited by this paper
• Treatment

  1973cited by this paper

• In vivo neuroprotection in ischemic stroke by activated protein C requires β-arrestin 2

  2024cites this paper
• Management of Acute Cerebral Infarction by Intravenous Thrombolysis with Recombinant T Cell Receptor and Plasminogen Activator and Association of Emergency Nursing Route in the Prognosis.

  2023cites this paper
• TRIM9-Mediated Resolution of Neuroinflammation Confers Neuroprotection upon Ischemic Stroke in Mice

  2023cites this paper
• Therapeutic management of ischemic stroke

  2023cites this paper
• Now that the door is open: an update on ischemic stroke pharmacotherapeutics for the neurointerventionalist

  2023cites this paper
• Neuroprotection in Acute Ischemic Stroke: A Battle Against the Biology of Nature

  2022cites this paper
• 3K3A-Activated Protein C Protects the Blood-Brain Barrier and Neurons From Accelerated Ischemic Injury Caused by Pericyte Deficiency in Mice

  2022cites this paper
• Neuroprotective approach in acute ischemic stroke: A systematic review of clinical and experimental studies

  2022cites this paper
• Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C

  2021cites this paper
• Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation

  2021cites this paper
• Antithrombotic Agents for tPA‐Induced Cerebral Hemorrhage: A Systematic Review and Meta‐Analysis of Preclinical Studies

  2020cites this paper
• Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.

  2020cites this paper
• Activated Mesenchymal Stem Cells Induce Recovery Following Stroke Via Regulation of Inflammation and Oligodendrogenesis

  2020cites this paper
• TRIM9-Mediated Resolution of Neuroinflammation Confers Neuroprotectionupon Ischemic Stroke in Mice

  2019cites this paper
• β-arrestin-2 in PAR-1-biased signaling has a crucial role in endothelial function via PDGF-β in stroke

  2019cites this paper
• 3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice

  2019cites this paper
• Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss

  2019cites this paper
• tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use?

  2019cites this paper
• Neuroprotection and vasculoprotection using genetically targeted protease-ligands.

  2019cites this paper
• Lipidomics study of the protective effects of isosteviol sodium on stroke rats using ultra high‐performance supercritical fluid chromatography coupling with ion‐trap and time‐of‐flight tandem mass spectrometry

  2018cites this paper
• Salidroside improves brain ischemic injury by activating PI3K/Akt pathway and reduces complications induced by delayed tPA treatment

  2018cites this paper
• Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke

  2018cites this paper
• The investigation of protective effects of isosteviol sodium on cerebral ischemia by metabolomics approach using ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry.

  2018cites this paper
• Early administration of pyrrolidine dithiocarbamate extends the therapeutic time window of tissue plasminogen activator in a male rat model of embolic stroke

  2018cites this paper
• Potential molecular targets of peroxynitrite in mediating blood–brain barrier damage and haemorrhagic transformation in acute ischaemic stroke with delayed tissue plasminogen activator treatment

  2018cites this paper
• PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke.

  2018cites this paper
• Key Points * R 41 Q and R 46 Q point mutations in PAR 1 in mice enabled studies of APC ’ s in vivo mechanism of action in lethal sepsis and ischemic stroke

  2018cites this paper
• Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research

  2017cites this paper
• Adequate Platelet Function Inhibition Confirmed by Two Inductive Agents Predicts Lower Recurrence of Ischemic Stroke/Transient Ischemic Attack

  2017cites this paper
• Extract of Spatholobus suberctus Dunn ameliorates ischemia-induced injury by targeting miR-494

  2017cites this paper
• Rapamycin prevents cerebral stroke by modulating apoptosis and autophagy in penumbra in rats

  2017cites this paper
• Hematoma Expansion Following Intracerebral Hemorrhage: Mechanisms Targeting the Coagulation Cascade and Platelet Activation.

  2017cites this paper
• One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke

  2017cites this paper
• Endothelial protein C receptor-dependent antichemotactic effects of canine protein C.

  2017cites this paper
• Inflammation: the Common Link in Brain Pathologies

  2016cites this paper
• Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke

  2016cites this paper
• Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection

  2016cites this paper
• 2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.

  2016cites this paper
• Influence of miR-155 on Cell Apoptosis in Rats with Ischemic Stroke: Role of the Ras Homolog Enriched in Brain (Rheb)/mTOR Pathway

  2016cites this paper
• 3K3A–activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice

  2016cites this paper
• Activated protein C promotes neuroprotection: mechanisms and translation to the clinic.

  2016cites this paper
• Astrocyte tissue factor controls CNS hemostasis and autoimmune inflammation.

  2016cites this paper
• Therapeutic benefits of combined treatment with tissue plasminogen activator and 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-d-pyranoside in an animal model of ischemic stroke.

  2016cites this paper
• 51 – Intravenous Thrombolysis

  2016cites this paper
• Neuroinflammation in Ischaemic Stroke: Utilizing the Biphasic Niche of Neuroprotection and Neurotoxicity for Clinic

  2016cites this paper
• Einfluss von doppelsträngiger RNA auf die Thrombusbildung in der Mikrozirkulation der Maus

  2016cites this paper
• Glial Support of Blood–Brain Barrier Integrity: Molecular Targets for Novel Therapeutic Strategies in Stroke

  2016cites this paper
• Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases

  2016cites this paper
• Thrombotic Stroke : Neuroprotective Therapy by Recombinant-Activated Protein C

  2016cites this paper
• Activated protein C: biased for translation.

  2015influential citation
• Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke.

  2015cites this paper
• Activated protein C β-glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury.

  2015cites this paper
• Protective effects of activated protein C (APC) on free groin flaps after secondary venous stasis in the rat model

  2015cites this paper
• Protective Effects of Non-Anticoagulant Activated Protein C Variant (D36A/L38D/A39V) in a Murine Model of Ischaemic Stroke

  2015cites this paper
• THROMBOSIS AND HEMOSTASIS Activated protein C b-glycoform promotes enhanced noncanonical PAR 1 proteolysis and superior resistance to ischemic injury

  2015cites this paper
• Cytoprotective-selective activated protein C therapy for ischaemic stroke

  2014cites this paper
• Protease activated receptor-1 mediates cytotoxicity during ischemia using in vivo and in vitro models.

  2014cites this paper
• mTOR Signaling Inhibition Modulates Macrophage/Microglia-Mediated Neuroinflammation and Secondary Injury via Regulatory T Cells after Focal Ischemia

  2014cites this paper
• Neuroprotection in Stroke: Past, Present, and Future

  2014cites this paper
• Thrombomodulin--a new target for treating stroke at the crossroad of coagulation and inflammation.

  2014cites this paper
• Recombinant T Cell Receptor Ligand Treatment Improves Neurological Outcome in the Presence of Tissue Plasminogen Activator in Experimental Ischemic Stroke

  2014cites this paper
• via Regulatory T Cells after Focal Ischemia Neuroinflammation and Secondary Injury Macrophage/Microglia-Mediated mTOR Signaling Inhibition Modulates

  2014cites this paper
• Effects of Exogenous Recombinant APC in Mouse Models of Ischemia Reperfusion Injury and of Atherosclerosis

  2014cites this paper
• Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers.

  2014cites this paper
• Gain in translation: heme oxygenase‐1 induced by activated protein C promotes thrombus resolution

  2014cites this paper
• Thrombin regulation of synaptic plasticity: implications for physiology and pathology.

  2013cites this paper
• High dose infusion of activated protein C (rhAPC) fails to improve neuronal damage and cognitive deficit after global cerebral ischemia in rats.

  2013cites this paper
• Immunoregulatory proteases in systemic lupus erythematosus and lupus nephritis

  2013cites this paper
• Influence of the 3K3A‐activated protein C variant on the plasma clot lysis activity of t‐PA and of t‐PA on the variant's anticoagulant activity

  2013cites this paper
• Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1.

  2013cites this paper
• Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice.

  2013cites this paper
• An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR1-Akt Pathway

  2013cites this paper
• Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats

  2013influential citation
• Immunoregulatory Proteases in Systemic Lupus Erythematosus and Lupus Nephritis

  2013cites this paper
• Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats

  year unknowncites this paper